Camptomelic Dysplasia

Campomelic dysplasia is one of the rarest of the named skeletal dysplasias. No reliable population incidence figure was retrievable for this page, and quoting one would be invented - describe it to an examiner as a rare, historically lethal dysplasia rather than attaching a number to it. What can be stated with confidence is its genetics and its ascertainment pattern:

• Autosomal dominant, usually de novo. Heterozygous loss of SOX9 function causes the condition; most patients are sporadic, so the parents are typically unaffected and the recurrence risk is low - but not zero, because germline mosaicism is documented (see the Higeta family in the evidence section).
• Ascertainment is bimodal. The severe end is identified antenatally (bowed long bones and a small thorax on ultrasound) or in the delivery room with respiratory failure; the milder end - including the acampomelic variant - surfaces later, sometimes only when a straight-limbed child with scoliosis and hypoplastic scapulae is sequenced.
• Both sexes, one karyotype trap. Because many 46,XY individuals are sex-reversed with female or ambiguous genitalia, the condition may present as a phenotypic girl with a bowing dysplasia; the karyotype is part of the diagnosis, not an afterthought.
• Where it sits in the differential. Among the lethal fetal/neonatal dysplasias it is less common than thanatophoric dysplasia and osteogenesis imperfecta type II, which together account for roughly half of cases coming to perinatal autopsy in the Jezova series; campomelic dysplasia sits in the next tier alongside achondrogenesis type 2, short-rib dysplasias and chondrodysplasia punctata.

• The gene. SOX9 (an SRY-box transcription factor) maps to chromosome 17q24.3. It is a master regulator of two processes that explain the whole phenotype: chondrogenesis (cartilage/skeletal and airway development - hence the bowing, small thorax and laryngotracheomalacia) and testis determination (hence the XY sex reversal).
• Two molecular mechanisms. Campomelic dysplasia results from heterozygous loss of SOX9 function by either route:
  1. Intragenic mutations - point or truncating mutations WITHIN the SOX9 coding region (the majority of cases, usually arising de novo, autosomal dominant).
  2. Chromosomal rearrangements upstream of SOX9 - translocations, inversions or deletions in the large regulatory region up to about 1 Mb upstream that separate SOX9 from its distant tissue-specific enhancers (a position effect / cis-regulatory disruption). These extragenic rearrangements are more often associated with the milder or acampomelic (straight-bone) phenotypes.
• Inheritance and counselling. Most cases are de novo (low recurrence risk), but germline mosaicism in an apparently unaffected parent means the recurrence risk is not zero - there is a molecularly confirmed family in which maternal germinal mosaicism produced two affected siblings, and the mother's mosaicism was only suspected because radiographs showed mild skeletal changes. Examine and image both parents before quoting a negligible recurrence risk.

View larger

The most severe and lethal skeletal dysplasias are identifiable before birth, and an increasing proportion are confirmed by genetic testing antenatally - so the diagnosis is often first suspected on a scan rather than in the delivery room.

• Antenatal ultrasound features. Shortened and bowed long bones (especially the femora and tibiae), a narrow/small thorax with a reduced chest circumference (predicting the lethal pulmonary hypoplasia that drives mortality), hypoplastic or absent scapulae, and sometimes micrognathia/cleft palate. The bowing plus a small thorax is the key pattern.
• A powerful clue. Discordance between a 46,XY karyotype and female-appearing genitalia on antenatal assessment strongly suggests the SOX9 diagnosis rather than another lethal dysplasia.
• Confirmation. Definitive prenatal diagnosis is molecular - SOX9 sequencing and karyotype on chorionic villus sampling or amniocentesis - particularly where there is a suggestive scan or a family history.
• Why it matters. Recognising a lethal phenotype prenatally allows honest counselling, the option of termination, and planning of delivery and neonatal care (a palliative pathway versus active airway/respiratory support). The differential on antenatal ultrasound includes other lethal dysplasias such as thanatophoric dysplasia and osteogenesis imperfecta type II.

Management is dictated by the airway first and the skeleton second, and the honest framing for the family is that this is a historically lethal condition in which survival beyond infancy is now reported but cannot be promised.

• Respiratory failure is the dominant early complication and the usual cause of death: the small thorax plus multi-level airway obstruction (Pierre Robin above, laryngotracheomalacia below) produces respiratory failure that is frequently fatal neonatally. No reliable survival percentage was retrievable, so none is quoted - the condition is described as historically lethal with survival into childhood and beyond now reported.
• Multi-level airway obstruction is itself the complication that defeats single-level solutions; a child who remains obstructed after intubation or tracheostomy has not been fully assessed.
• Progressive kyphoscoliosis in survivors threatens an already small thorax and can worsen restrictive lung disease over time - the reason spinal surveillance continues to skeletal maturity.
• Feeding difficulty, failure to thrive and recurrent respiratory infection accompany the airway and palatal anomalies.
• Gonadal and psychosocial sequelae of the sex reversal require long-term DSD follow-up; the counselling errors made in infancy are not correctable later.
• Recurrence in a future pregnancy is the complication the family fears most after a de novo case; germline mosaicism means the risk is low but real, and prenatal diagnosis (ultrasound plus SOX9 testing on CVS/amniocentesis) is available for subsequent pregnancies.